Substance / Medication

Quazepam

Overview

Active Ingredient
quazepam
RxNorm CUI
35185

Indications

Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often

Labeler: Atland Pharmaceuticals, LLCUpdated: 2025-10-23T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

5.1 7 [see Warnings and Precautions (), Drug Interactions ()] Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Lim

Contraindications

When this intervention should not be used

Quazepam Tablets are contraindicated in patients with known hypersensitivity to quazepam or other benzodiazepines. Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of Quazepam Tablets. Some patients have had ad

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effects of quazepam as a preoperative night hypnotic: comparison with brotizolam.
Nishiyama Tomoki, Yamashita Koichi, Yokoyama Takeshi et al. · J Anesth · 2007
PMID: 17285406Observational
Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam.
Sugimoto Koh-ichi, Araki Nobutaka, Ohmori Masami et al. · Eur J Clin Pharmacol · 2006
PMID: 16416305Observational
Quantitative analysis of quazepam and its metabolites in human blood, urine, and bile by liquid chromatography-tandem mass spectrometry.
Zhou Jing, Yamaguchi Koji, Ohno Youkichi · Forensic Sci Int · 2014
PMID: 24856286Case Report
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
Moniri Nader H · Int Clin Psychopharmacol · 2019
PMID: 31274695Review
Stereochemical properties of quazepam and its affinity for the GABAreceptor.
Takano Ryota, Tanaka Ryoko, Nakamura Kayo et al. · Bioorg Med Chem Lett · 2024
PMID: 38914347Other
Structural analysis of quazepam metabolites in bile by ion trap time-of-flight mass spectrometry.
Yamaguchi Koji, Goda Takahiro, Yamaki Satoshi et al. · Forensic Sci Int · 2015
PMID: 26301753Other
Analysis of quazepam and its metabolites in human urine by gas chromatography-mass spectrometry: application to a forensic case.
Terada Masaru, Shinozuka Tatsuo, Hasegawa Chika et al. · Forensic Sci Int · 2013
PMID: 23290298Other
Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity.
Fukasawa Takashi, Yasui-Furukori Norio, Aoshima Toshiaki et al. · Ther Drug Monit · 2004
PMID: 15385836Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Quazepam (substance)
SNOMED CT
108391004
UMLS CUI
C0072828
RxNorm CUI
35185
Labeler
Atland Pharmaceuticals, LLC

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.